When a Complex Case Needs Structured Review
Many physicians facing a complex oncology case do not need more information — they need better-organized information. CancerCareE helps clarify the clinical question, find the relevant evidence, identify what remains unknown, and — where relevant — locate clinical trials and international access options worth exploring.
This is a structured evidence review service. It is not a medical second opinion, not a tumor board decision, and not a guarantee of access, eligibility, or outcome.
Quick Answer
CancerCareE provides a structured Evidence Review service for referring physicians. The service organizes publicly available evidence, clarifies the clinical question, identifies relevant studies and trials, and explicitly flags what remains unknown or unverified. It does not replace clinical judgment, does not constitute a medical second opinion, and does not guarantee admission to any institution.
The Missing-Step Problem
Common assumption: "If a physician can search PubMed, they can find the answer themselves."
Reality: The difficult part is rarely finding any study. It is knowing which studies are actually relevant to this specific patient, what their limitations are, whether a given therapy is available in a given country, and which questions still need to be answered before the next step can be taken. CancerCareE helps with that missing step.
What This Service Is — and What It Is Not
This service IS
- A structured review of publicly available evidence
- A way to clarify the clinical question and its scope
- A source for identifying relevant trials and access conditions
- Physician-led and patient-consented
This service IS NOT
- A medical second opinion or tumor board decision
- A guarantee of eligibility, admission, or outcome
- A substitute for clinical judgment
- A medical tourism or patient brokerage service
Four Situations Where Structured Review May Help
Each situation has a different underlying question. They share one entry point — but they do not need four separate forms.
Referring Oncologist
The patient has received multiple lines of therapy with inadequate response, and the physician wants to structure the clinical question before deciding on the next step.
Physician Seeking Trials
The physician suspects a relevant trial may exist but needs help locating the right one, understanding eligibility criteria, and verifying registry status.
Physician or Family Exploring International Access
A therapy may appear promising in the literature, but the patient's family needs help distinguishing scientific evidence from regulatory status, admission requirements, cost, and practical access.
Referring Institution or Specialized Center
A case is referred with an unclear question or incomplete context. The goal is to standardize what should be provided before a referral proceeds.
Important: These are not four separate services. They share a common entry point and are routed based on the specific clinical question.
What Is Available — and What Is in Development
CancerCareE recognizes three distinct levels of case support. Only the first is currently offered. The others are being developed and are listed here for transparency.
Level 1 — Evidence Review
A structured, publicly-sourced review of available evidence, relevant trials, and access conditions for a specific clinical question.
- Definition and scoping of the clinical question
- Search of authoritative sources (PubMed, registries, regulatory bodies)
- Identification of relevant studies and their limitations
- Review of registry status for relevant trials
- Explicit documentation of what remains unknown
Level 2 — Specialist Second Opinion
A review of a specific case by a qualified physician with a clearly defined scope, professional accountability, and appropriate legal framework.
- Review by a credentialed specialist
- Clear scope and limitations of the opinion
- Disclosure of relevant professional and financial relationships
- Not currently offered as a service
Level 3 — Multispecialist Case Conference
A structured conference involving multiple independent specialists, with documented areas of consensus and disagreement.
- Independent opinions, if genuinely independent
- Documentation of consensus and divergence
- Defined rules for selection and conflict management
- Not currently offered as a service
Note: Levels 2 and 3 are not currently offered. They are listed here so physicians understand the direction of the service — not as current offerings.
Structure of an Evidence Review Output
The output is a structured document. It is not a treatment recommendation, and it is not a medical opinion.
Evidence Review — Illustrative Structure
This is a structural example only. No patient identifiers. No medical second opinion. No treatment recommendation.
1. Clinical Question
The specific clinical question as scoped by the referring physician.
2. Sources Consulted
- Public registry records (ClinicalTrials.gov, WHO ICTRP)
- Published clinical literature
- Regulatory authority information
- Partner institution confirmations (where available)
3. Findings
Relevant studies and trials, with their sources and published limitations.
4. Limitations and Unknowns
- Where evidence is uncertain or limited
- Where registry status has not been verified
- Where access conditions remain unconfirmed
- Where patient-specific data would be required for further assessment
5. Open Questions
Questions that remain unresolved, with a proposed next step for considering them.
6. References
Direct links to sources used, so the physician can verify the underlying information independently.
Five Commitments
Physician-led decisions
Clinical decisions remain with the treating physician and the patient.
Informed patient consent
Any introduction or sharing of information proceeds only with the patient's awareness and consent.
Evidence-linked information
Scientific and regulatory claims are linked to publicly verifiable sources.
Transparent access conditions
Unknown or unverified status is not hidden — it is clearly flagged.
Financial transparency
Any financial relationship relevant to an introduction is disclosed. See Financial Transparency.
Clinical Need → Required Capability → Potential Access Paths
A general framework for evaluating whether an international pathway is worth exploring further. Illustrative only — not specific recommendations.
| Clinical Need | Required Capability | Potential Access Paths |
|---|---|---|
| Patient has exhausted standard local treatment lines | Availability of investigational or regionally approved therapies | Public trial registries; partner institutions; documented access requirements |
| Rare molecular target with limited published data | Site-specific experience and protocol availability | Registry-based trial search; direct site inquiry; peer literature review |
| Therapy approved in one jurisdiction but not another | Regulatory status and cross-border access conditions | Regulatory authority records; partner institution confirmation |
| Patient requires treatment coordination abroad | Feasibility of travel, documentation, and continuity of care | Partner institutions; documented logistics and repatriation planning |
Frequently Asked Questions
What exactly does CancerCareE provide?
Currently, CancerCareE provides a structured Evidence Review: a document that organizes publicly available evidence, identifies relevant studies and trials, and explicitly states what remains unknown or unverified. Levels 2 (Specialist Second Opinion) and 3 (Multispecialist Case Conference) are in development.
Is this a medical second opinion?
No. This is not a medical second opinion. It is a structured review of publicly available evidence, meant to support — not replace — the treating physician's own judgment. A separate Specialist Second Opinion service is in development and will be clearly labeled when available.
What information is needed to begin?
Only the clinical context required to understand the question — cancer type, prior lines of therapy, relevant molecular findings, and the specific clinical question the physician is trying to answer. No full medical records and no identifiable patient data are requested through this website.
Does CancerCareE guarantee a response time?
No. Response times depend on the complexity of the question and the availability of relevant sources. We will confirm an expected timeline with the referring physician once the request is received.
Is there a cost for the referring physician?
The Evidence Review service is free of charge to referring physicians. Any financial relationship relevant to an introduction is disclosed on the Financial Transparency page.
How is patient data handled?
No full medical records are requested through this website. Any information shared for an initial review should be de-identified and limited to the clinical context needed to understand the question. We do not store personal health information on this website.
What is CancerCareE's role in this process?
CancerCareE is an independent information platform. We organize publicly available evidence and access information into a structured format. We are not a healthcare provider, we do not make clinical decisions, and our role ends when the physician no longer requires the review.
What if the review finds that no meaningful next step is available?
If no realistic next step can be identified, we will say so — with reasons. A referral to CancerCareE does not commit the physician or patient to any further step, and does not trigger any obligation.
Explore a Structured Review for Your Patient
Start with a minimal request. We will use the information provided to determine whether a meaningful review is possible, and reply with next steps.
Continue Your Clinical Research
Sources and Further Reading
- U.S. National Library of Medicine — ClinicalTrials.gov. Public registry of clinical studies. Available at: clinicaltrials.gov
- World Health Organization — International Clinical Trials Registry Platform (ICTRP). Available at: who.int/clinical-trials-registry-platform
- U.S. Food and Drug Administration — Oncology guidance documents. Available at: fda.gov
- European Medicines Agency — Oncology product information. Available at: ema.europa.eu
- National Medical Products Administration (NMPA), China — Regulatory information. Available at: nmpa.gov.cn
- PubMed — Biomedical literature database. Available at: pubmed.ncbi.nlm.nih.gov